Every 10-Q that Blade Air Mobility, Inc. (BLDE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BLDE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLDE filings page.
Strata Critical Medical delivered strong growth and turned profitable in the quarter ended March 31, 2026. Revenue rose to $67.4 million from $35.9 million, driven by 32.4% growth in Logistics to $47.6 million and new Clinical revenue of $19.8 million from the Keystone acquisition.
Gross profit doubled to $14.1 million, lifting total gross margin to 21.0% as higher‑margin Clinical work scaled. After $5.4 million of other non‑operating income, mainly fair value changes, Strata posted net income of $2.2 million versus a $3.5 million loss a year earlier, including a small loss from discontinued Passenger operations.
The company ended the quarter with $58.7 million in cash and cash equivalents, total assets of $327.6 million and stockholders’ equity of $285.7 million. A new $30 million asset‑based revolving credit facility was put in place and remained undrawn, providing additional liquidity for working capital and growth.
Strata Critical Medical (formerly Blade) reported Q3 2025 results highlighting a strategic pivot to healthcare services. Revenue from continuing operations reached $49,298 (vs. $36,062 a year ago), while operating loss narrowed to $5,622. The quarter’s net income of $57,416 was driven by discontinued operations following the Passenger business sale.
On August 29, Strata sold its Passenger business to a Joby Aviation subsidiary for consideration valued at $75,357 in Joby shares and later sold those shares for net proceeds of $70,163. The company may receive up to an additional $35,000 based on performance and retention targets, plus up to $10,000 in indemnity holdbacks. On September 16, Strata acquired Keystone Perfusion Services for $109,963 in cash and 3,434,609 shares valued at $16,828, adding $69,067 of goodwill and $42,600 of identifiable intangibles.
Cash and cash equivalents were $22,753 and short‑term investments were $53,165 as of September 30, 2025. Basic and diluted EPS were $0.70, reflecting a continuing operations loss of $0.12 and discontinued operations income of $0.81. Shares outstanding were 86,366,526 as of November 3, 2025.
Blade Air Mobility (NASDAQ: BLDE) Q2 2025 10-Q highlights
- Revenue rose 4% YoY to $70.8 m; Medical segment up 18% to $45.1 m, offsetting a 13% Passenger decline to $25.7 m.
- Cost discipline: Total operating expenses fell 5% to $75.8 m, driven by a 20% reduction in G&A and 32% lower selling & marketing spend.
- Profitability improving: Operating loss narrowed to $(5.0) m from $(12.1) m; net loss trimmed to $(3.7) m (-$0.05/sh) versus $(11.3) m (-$0.15/sh) prior-year.
- Segment Adjusted EBITDA grew 34% to $8.4 m; Medical contributed $6.0 m.
- Liquidity: Cash & equivalents $58.8 m plus $54.7 m short-term Treasuries; operating cash burn cut to $3.3 m (vs $7.1 m).
- Balance sheet: Warrant liability marked down to $3.0 m (from $5.8 m); goodwill now $44.3 m after organ-transport acquisitions.
- Share count: 81.7 m shares outstanding, up 2.3 m YTD due to equity compensation; stock-based comp $9.6 m YTD.
- Subsequent event: 1 Aug 25 agreement to sell Passenger business to Joby Aviation for up to $125 m ($90 m at close, $35 m earn-out, cash or JOBY stock). Transaction expected to be treated as discontinued operations.
- Guidance: none provided; management notes seasonality with stronger Q2–Q3 passenger demand.
Key takeaways: Blade is pivoting toward its higher-margin Medical segment while monetizing the Passenger operation. Liquidity remains solid and losses are shrinking, but execution risk on the Joby deal and continued passenger softness warrant monitoring.